Market Cap | 43.68M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -83.41M | Forward P/E | -1.32 | EPS next Y | - | 50D Avg Chg | 15.00% |
Sales | 2.56M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -32.00% |
Dividend | N/A | Price/Book | 0.39 | EPS next 5Y | - | 52W High Chg | -89.00% |
Recommedations | 2.00 | Quick Ratio | 4.24 | Shares Outstanding | 44.55M | 52W Low Chg | 68.00% |
Insider Own | 22.40% | ROA | -26.83% | Shares Float | 27.66M | Beta | 3.01 |
Inst Own | 25.07% | ROE | -85.91% | Shares Shorted/Prior | 223.18K/345.38K | Price | 0.99 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 70,845 | Target Price | 6.00 |
Oper. Margin | -2,516.28% | Earnings Date | May 2 | Volume | 34,635 | Change | 5.81% |
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Chardan Capital | Buy | Aug 15, 23 |
Chardan Capital | Buy | May 11, 23 |
Morgan Stanley | Equal-Weight | Mar 24, 23 |
Chardan Capital | Buy | Mar 23, 23 |
Chardan Capital | Buy | Jan 30, 23 |
Morgan Stanley | Equal-Weight | Jan 27, 23 |
JP Morgan | Neutral | Dec 16, 22 |
Morgan Stanley | Equal-Weight | Oct 7, 22 |
B of A Securities | Buy | Sep 29, 22 |